Abbott Case Reflects FDA Focus On "Medically Necessary" Product GMPs
The recent Abbott consent decree should alert manufacturers that FDA is serious about GMP compliance for "medically necessary" products, FDA Deputy Chief Counsel for Litigation Eric Blumberg told the Food & Drug Law Institute meeting in Washington, D.C. Dec. 17.
More from Archive
More from Pink Sheet
During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.
US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.
US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.